Treatment of Newly Diagnosed Glioblastoma in Patients Younger Than 65–70 Years with Good Functional Status and MGMT Promoter Methylation
This first-line protocol addresses management of glioblastoma at initial diagnosis in patients who are younger than 65–70 years, maintain good functional status, and whose tumors carry MGMT promoter methylation — a molecular profile that shapes the treatment decision.
Clinical Scenario
Newly diagnosed
Age < 65–70 yrs
Good functional status
MGMT promoter methylated
Treatment decisions for glioblastoma at initial diagnosis depend on age, functional status, MGMT promoter methylation status, and patient care goals. For patients in this group — younger than 65–70 years with good performance status and a methylated MGMT promoter — participation in clinical trials is highly recommended given the modest benefits of standard approaches.
Treatment Approach (Partial Overview)
Management begins with a surgical consideration, with maximal safe resection as the primary goal where feasible. The criteria that determine which surgical option applies, and what alternatives come into play when open resection is not optimal, are fully detailed in the structured protocol.
References
DOI: 10.1093/neuonc/noaf177
- Treatment decisions for glioblastoma after maximal safe resection depend on age, functional status, MGMT status, and patient care goals (Figure 8).
- Given the modest benefits of standard treatments, participation in clinical trials is highly recommended for patients with good performance status of any age.
- Nevertheless, the goal for glioblastoma surgery should be maximal safe resection of the enhancing and non-enhancing solid tumor whenever feasible.
- Whenever microsurgical resection is deemed to be too risky based on the patient's medical condition and/or the functional topography of the affected brain region, a stereotactic or open biopsy should be performed to obtain a histological and molecular diagnosis.
- For patients in whom conventional, open surgical approaches are not deemed optimal because of surgical risk, MRI-guided laser interstitial thermal therapy, a minimally invasive technique designed to ablate tumors, is sometimes an option.
View source ↗